Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyra Therapeutics, Inc. (Nasdaq: LYRA) SEC filings page on Stock Titan provides access to the company’s public reports and current reports filed with the U.S. Securities and Exchange Commission. Lyra identifies itself in these filings as a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS), with its common stock listed on The Nasdaq Capital Market under the symbol LYRA.
Through Lyra’s Forms 10-K and 10-Q, readers can review detailed financial statements, including collaboration revenue, research and development expenses related to the ENLIGHTEN Phase 3 clinical program for LYR-210, general and administrative costs, restructuring charges, and cash and cash equivalents balances. These periodic reports also describe the company’s status as a clinical-stage entity with no approved products and discuss risks such as ongoing losses, funding needs, and dependence on clinical trial outcomes.
Current reports on Form 8-K document material events that are important for understanding LYRA’s situation. Examples include notices from The Nasdaq Stock Market regarding compliance with listing requirements, such as minimum bid price and stockholders’ equity thresholds; details of a registered direct offering and concurrent private placement of warrants; and changes in board and executive roles. Other 8-K filings reference the posting of corporate presentations that discuss LYR-210 and the ENLIGHTEN clinical program.
For those interested in clinical and strategic developments, Lyra’s filings and attached exhibits often cross-reference press releases that summarize ENLIGHTEN 2 Phase 3 results, pooled analyses in patients with nasal polyps, and regulatory interactions with the U.S. Food and Drug Administration. More recent corporate updates, including the decision by Lyra’s Board of Directors to suspend further development of LYR-210 and cease product development operations, are reflected in company disclosures and provide important context for interpreting financial and risk disclosures.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered tools can help readers quickly identify key sections in lengthy reports, such as risk factors, management’s discussion and analysis, restructuring notes, and disclosures related to Nasdaq listing status, financing agreements, and strategic alternatives under consideration.
Lyra Therapeutics director and Principal Executive Officer Maria Palasis reported returning 2,000 shares of Common Stock to the company in a disposition to the issuer at $0.00 per share. After this transaction, she directly owns 1,094,733 shares, indicating only a small portion of her holdings was affected.
Lyra Therapeutics Principal Financial Officer Jason Cavalier returned 667 shares of Common Stock to the company. The disposition to the issuer carried a reported price of $0.00 per share. After this transaction, he directly owns 517,880 shares, indicating this was a small, routine adjustment to his holdings.
Lyra Therapeutics reports in its annual filing that it has suspended further development of LYR-210, its lead chronic rhinosinusitis treatment, and implemented deep cost reductions, including layoffs affecting substantially all remaining employees. The company is pursuing strategic alternatives such as a merger, sale, or asset transactions but notes there is no assurance any deal will occur or be attractive.
Lyra highlights serious financial strain, with operating losses of approximately $31.0 million in 2025 and $96.3 million in 2024 and acknowledges substantial doubt about its ability to continue as a going concern. It is attempting to sublease or assign costly leases, while facing delisting from the Nasdaq Capital Market and potential classification as a public shell company, which could severely limit liquidity, capital-raising options, and use of Rule 144 and Form S‑3. The company has positive Phase 3 ENLIGHTEN 2 data for LYR-210 and an extensive patent estate potentially extending to 2042, but any renewed development would require significant new funding or a strategic transaction.
Lyra Therapeutics, Inc. reported that it has withdrawn its appeal of Nasdaq’s February 2, 2026 delisting determination. As a result, Nasdaq has confirmed that trading in the company’s common stock will be suspended at the open of trading on Tuesday, March 17, 2026.
Nasdaq has also indicated it will file a Form 25 Notification of Delisting with the SEC after its internal procedural periods are completed. The company’s shares are currently listed on The Nasdaq Capital Market under the symbol LYRA.
Lyra Therapeutics, Inc. reported that on February 23, 2026 it received a notice of default from RVAC Medicines (US), Inc. under its sublease for office space in Waltham, Massachusetts. The default stems from unpaid rent invoices from the master landlord totaling $484,431.92 as of the notice date.
The company previously disclosed that it is ceasing operations and preparing for a wind-down while pursuing strategic options, and has been trying to settle obligations, including lease liabilities, outside a bankruptcy process. Lyra had proposed terminating the sublease with a premises surrender date of January 31, 2026, but no agreement was reached before rent payments stopped.
Lyra states it is continuing to evaluate options regarding the sublease and other outstanding obligations as part of its wind-down. It cautions that there can be no assurance it will successfully negotiate a termination or otherwise resolve these obligations outside of a bankruptcy process, highlighting significant uncertainty around remaining liabilities.